Lenvatinib Export Market Intelligence: India's 127 Suppliers Shipping to 74 Countries — TransData Nexus 2026

Q: Who are the top lenvatinib exporters from India?

The top lenvatinib exporters from India are: 1. SUN PHARMACEUTICAL INDUSTRIES LIMITED — $746.3K (35.0% market share); 2. SANDOZ PRIVATE LIMITED — $316.5K (14.8% market share); 3. PROSPERA LIFE SCIENCES PRIVATE LIMITED — $115.1K (5.4% market share); 4. BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED — $98.6K (4.6% market share); 5. GNH INDIA PHARMACEUTICALS LIMITED — $65.7K (3.1% market share). Together they account for 63.0% of India's total lenvatinib export value.

Q: What is the total export value of lenvatinib from India?

The total export value of lenvatinib from India is $2.1M USD, recorded across 863 shipment transactions from 127 active exporters to 74 destination countries. The average shipment value is $2.5K.

Q: Which countries import lenvatinib from India?

India exports lenvatinib to 74 countries worldwide. The top importing countries are: BRAZIL (38.3% share, $815.6K), SLOVENIA (14.6% share, $311.6K), THAILAND (6.8% share, $145.2K), UNITED ARAB EMIRATES (6.2% share, $132.0K), SINGAPORE (4.0% share, $85.0K). These five markets account for 69.9% of total export value.

Q: What is the HS code for lenvatinib exports from India?

The primary HS code for lenvatinib exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of lenvatinib exports from India?

The average unit price for lenvatinib exports from India is $95.11 USD per unit, with prices ranging from $0.01 to $17119.00 depending on formulation, packaging, and order volume. The total market is valued at $2.1M across 863 shipments.

Q: Which ports handle lenvatinib exports from India?

The primary ports for lenvatinib exports from India are SAHAR AIR CARGO ACC (INBOM4) (29.0% of shipments), SAHAR AIR (23.2% of shipments), DELHI AIR CARGO ACC (INDEL4) (8.8% of shipments), DELHI AIR (8.3% of shipments), Bombay Air (7.2% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of lenvatinib?

India is one of the world's leading exporters of lenvatinib due to its large base of 127 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports lenvatinib to 74 countries, demonstrating 38% global market coverage.

Q: What certifications do Indian lenvatinib exporters need?

Indian lenvatinib exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import lenvatinib from India?

There are 242 registered buyers importing lenvatinib from India, spread across 74 countries. The repeat buyer rate is 63.6%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top lenvatinib supplier from India?

SUN PHARMACEUTICAL INDUSTRIES LIMITED is the leading lenvatinib exporter from India with a market share of 35.0% and total export value of $746.3K across 5 shipments. The top 5 suppliers together control 63.0% of total export value.

Suresh Sormare

Lenvatinib

India Pharmaceutical Trade Intelligence

$2.1M127 Suppliers74 CountriesHS 30049099

ExportsIndia → BRAZIL38.3%India → SLOVENIA14.6%

ImportsUNITED STATES → India$110.3M JAPAN → India$1.2M

#1 Supplier: SUN PHARMACEUTICAL #1 Buyer: LEK PHARMACEUTICALS

Lenvatinib Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Lenvatinib to the World

Between 2022 and 2026, India exported $2.1M worth of lenvatinib across 863 verified shipments to 74 countries — covering 38% of world markets in the Advanced Oncology segment. The largest destination is BRAZIL (38.3%). SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 35.0% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Lenvatinib export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Lenvatinib export data snapshot — $2.1M · 127 exporters · 74 countriesTransData Nexus · Indian Customs Data

Top Lenvatinib Exporters from India

127 active exporters · Ranked by export value

View all 127 →

Top Lenvatinib Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$746.3K	5	1	35.0%
2	SANDOZ PRIVATE LIMITED

Top Countries Importing Lenvatinib from India

74 destination markets · Ranked by import value

All 74 countries →

Top Countries Importing Lenvatinib from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	BRAZIL	$815.6K	38.3%
2	SLOVENIA	$311.6K	14.6%
3	THAILAND	$145.2K	6.8%
4	UNITED ARAB EMIRATES	$132.0K	6.2%
5	SINGAPORE	$85.0K	4.0%
6	SPAIN	$66.6K	3.1%
7	EGYPT	$65.5K	3.1%
8	KAZAKHSTAN	$49.5K	2.3%
9	LAOS	$37.6K	1.8%
10	PHILIPPINES	$37.5K	1.8%

BRAZIL is India's largest lenvatinib export destination, absorbing 38.3% of total exports worth $815.6K. The top 5 importing countries — BRAZIL, SLOVENIA, THAILAND, UNITED ARAB EMIRATES, SINGAPORE — together account for 69.9% of India's total lenvatinib export value. The remaining 69 destination countries collectively receive the other 30.1%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Lenvatinib to India?

14 origin countries · Total import value: $112.1M

India imports lenvatinib from 14 countries with a combined import value of $112.1M. The largest supplier is UNITED STATES ($110.3M, 11 shipments), followed by JAPAN and CANADA. All values are from Indian Customs (DGFT) import records.

Countries Supplying Lenvatinib to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$110.3M	11	98.4%
2	JAPAN	$1.2M	12	1.0%
3	CANADA	$199.3K	13	0.2%
4	GERMANY	$178.6K	14	0.2%
5	SWITZERLAND	$123.6K	3	0.1%
6	BRAZIL	$40.1K	7	0.0%
7	UNITED KINGDOM	$37.4K	1	0.0%
8	AUSTRALIA	$29.8K	1	0.0%
9	SLOVENIA	$24.2K	25	0.0%
10	ISRAEL	$14.6K	25	0.0%

Showing top 10 of 14 origin countries

UNITED STATES is the largest supplier of lenvatinib to India, accounting for 98.4% of total import value. The top 5 origin countries — UNITED STATES, JAPAN, CANADA, GERMANY, SWITZERLAND — together supply 99.9% of India's lenvatinib imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Lenvatinib

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

As of March 2026, lenvatinib is approved in the United States under the brand name Lenvima, marketed by Eisai Co., Ltd. The U.S. Food and Drug Administration (FDA) granted initial approval for lenvatinib in February 2015 for the treatment of differentiated thyroid cancer. Subsequent approvals expanded its indications to include hepatocellular carcinoma in August 2018.

Regarding generic competition, Eisai has actively defended its intellectual property rights. In May 2025, the U.S. District Court for the District of New Jersey ruled in favor of Eisai in a patent infringement lawsuit against Shilpa Medicare Limited, preventing the approval of Shilpa's generic version of lenvatinib until after the patent's expiration in February 2036.

Given the absence of approved generic versions, the U.S. market for lenvatinib remains exclusive to the brand-name product. This exclusivity, coupled with the complex regulatory and patent landscape, presents challenges for Indian exporters aiming to enter the U.S. market.

2EU & UK Regulatory Framework

In the European Union, lenvatinib received marketing authorization from the European Medicines Agency (EMA) in May 2015 for the treatment of differentiated thyroid carcinoma refractory to radioactive iodine. The United Kingdom, following its departure from the EU, has maintained similar regulatory standards through the Medicines and Healthcare products Regulatory Agency (MHRA).

Compliance with Good Manufacturing Practice (GMP) standards is mandatory for pharmaceutical products in both the EU and UK. Indian exporters must ensure that their manufacturing facilities are GMP-certified to meet these stringent requirements.

3WHO Essential Medicines & Global Standards

As of the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, lenvatinib is not included. (who.int) Consequently, it is not part of the WHO Prequalification Programme. However, lenvatinib must comply with international pharmacopoeia standards, including those set forth by the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP).

4India Regulatory Classification

In India, lenvatinib is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for lenvatinib, allowing market-driven pricing. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations.

5Patent & Exclusivity Status

Lenvatinib is protected by patents in several jurisdictions, including the United States, where exclusivity extends until February 2036. This patent protection limits the entry of generic versions into the market, thereby affecting the competitive landscape for Indian exporters.

6Recent Industry Developments

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines. The 24th edition, published in September 2025, did not include lenvatinib, reflecting ongoing evaluations of its global health impact. (who.int)

In April 2025, the WHO launched the National Essential Medicines Lists (nEMLs) repository, a centralized digital platform compiling 150 national essential medicines lists. This resource aims to enhance access to critical healthcare data, supporting policymakers and healthcare professionals worldwide. (who.int)

These developments underscore the dynamic nature of the pharmaceutical regulatory environment and the importance of staying informed about changes that may impact the export and distribution of lenvatinib.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Lenvatinib

Retail & reference prices across 9 markets vs. India FOB export price of $95.11/unit

Global Price Benchmark for Lenvatinib across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$3.83	USD	According to the FDA Orange Book, Lenvatinib is approved for use in the United States.
United Kingdom	$3.90	GBP	As per the NHS Drug Tariff, Lenvatinib is listed for use within the National Health Service.
Germany	$3.85	EUR	The European Medicines Agency (EMA) has authorized the use of Lenvatinib in Germany.
Australia	$3.75	AUD

Supply Chain Risk Assessment — Lenvatinib

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). China controls approximately 70–80% of the global KSM supply and 60–70% of intermediates, making it a dominant player in the sector. This dependency poses significant risks, as any disruption in Chinese supply chains can directly impact India's pharmaceutical production. For instance, in November 2024, India inaugurated two greenfield plants under the Production Linked Incentive (PLI) scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, aiming to reduce import dependence on China.

The reliance on Chinese KSMs is particularly concerning for drugs like Lenvatinib, where the synthesis process depends on these materials. The concentration of KSM production in China means that any geopolitical tensions, trade restrictions, or production issues in China can lead to supply chain disruptions for Indian manufacturers. This structural dependency underscores the need for India to develop domestic capabilities in KSM and API production to ensure a stable supply chain.

2Supplier Concentration & Single-Source Risk

The export market for Lenvatinib is notably concentrated, with the top five exporters accounting for 63.0% of the total market share. SUN PHARMACEUTICAL INDUSTRIES LIMITED alone holds a 35.0% share, indicating a significant reliance on a few key suppliers. Such concentration increases the risk of supply chain disruptions if any of these major suppliers face operational challenges.

Access Complete Lenvatinib Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 863 transactions across 74 markets.

Request Demo View Pricing

Frequently Asked Questions — Lenvatinib Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top lenvatinib exporters from India?

The leading lenvatinib exporters from India are SUN PHARMACEUTICAL INDUSTRIES LIMITED, SANDOZ PRIVATE LIMITED, PROSPERA LIFE SCIENCES PRIVATE LIMITED, and 10 others. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with 35.0% market share ($746.3K). The top 5 suppliers together control 63.0% of total export value.

What is the total export value of lenvatinib from India?

The total export value of lenvatinib from India is $2.1M, recorded across 863 shipments from 127 active exporters to 74 countries. The average shipment value is $2.5K.

Which countries import lenvatinib from India?

India exports lenvatinib to 74 countries. The top importing countries are BRAZIL (38.3%), SLOVENIA (14.6%), THAILAND (6.8%), UNITED ARAB EMIRATES (6.2%), SINGAPORE (4.0%), which together account for 69.9% of total export value.

What is the HS code for lenvatinib exports from India?

The primary HS code for lenvatinib exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Lenvatinib

Lenvatinib

Top Lenvatinib Exporters from India

Top Countries Importing Lenvatinib from India

Who Supplies Lenvatinib to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Lenvatinib

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Lenvatinib

Supply Chain Risk Assessment — Lenvatinib

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Lenvatinib Trade Intelligence

Frequently Asked Questions — Lenvatinib Exports from India

Who are the top lenvatinib exporters from India?

What is the total export value of lenvatinib from India?

Which countries import lenvatinib from India?

What is the HS code for lenvatinib exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of lenvatinib exports from India?

Which ports handle lenvatinib exports from India?

Why is India a leading exporter of lenvatinib?

What certifications do Indian lenvatinib exporters need?

How many buyers import lenvatinib from India?

What is the market share of the top lenvatinib exporter from India?

Analysis Methodology